Neurawell Therapeutics
Clinical-stage research and development company focused on discovering and developing safe and effective therapeutics for central nervous system (CNS) disorders, with primary emphasis on major depressive disorder, treatment-resistant depression, and treatment-resistant anxiety. The company combines pharmacology, medicinal chemistry and reformulated delivery approaches with a patient-facing technical application to improve treatment adherence and manage side-effect and interaction risks.
Industries
Nr. of Employees
small (1-50)
Neurawell Therapeutics
Patents
Products
Lead CNS therapeutic candidate (small-molecule)
A reformulated small-molecule therapeutic candidate targeting treatment-resistant depressive and anxiety disorders, developed with an emphasis on mitigating serious side effects and improving patient compliance through delivery innovation.
NW-531
A unique molecule combined with an existing anti-depressant and coupled with a reformulated delivery mechanism to mitigate serious side effects and improve therapeutic compliance.
Lead CNS therapeutic candidate (small-molecule)
A reformulated small-molecule therapeutic candidate targeting treatment-resistant depressive and anxiety disorders, developed with an emphasis on mitigating serious side effects and improving patient compliance through delivery innovation.
NW-531
A unique molecule combined with an existing anti-depressant and coupled with a reformulated delivery mechanism to mitigate serious side effects and improve therapeutic compliance.
Expertise Areas
- Clinical trial management for CNS indications
- Medicinal chemistry and CNS pharmacology
- Drug metabolism and bioanalytical chemistry
- Drug-device combination development
Key Technologies
- Medicinal chemistry
- Drug metabolism and pharmacokinetic studies
- Bioanalytical assay development and validation
- Reformulated delivery systems